Thyroid stage III generally refers to stage III thyroid cancer. Differentiated thyroid cancer is characterized by high expression of vascular endothelial growth factor and its receptor, as well as genetic alterations such as BRAFV600E mutations, RET rearrangements, and RAS point mutations. Multikinase inhibitors acting on these targets prolong median progression-free survival and result in tumor shrinkage in some patients.
The multikinase inhibitor sorafenib may be considered for more rapidly progressing, symptomatic patients with advanced radioiodine-refractory differentiated thyroid cancer. The approved indication for sorafenib in China is locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer.
For advanced differentiated thyroid cancer that progresses more rapidly and is inoperable, the targeted therapy drug that has been approved for use in China is Anrotinib.
Patients with stage III thyroid cancer gene mutation are recommended to go to local regular hospitals as soon as possible to receive professional doctor’s treatment, so as not to delay the condition.